Private company

Dicerna Pharmaceuticals (United States)

Dicerna Pharmaceuticals (United States) is an American pharmaceutical preparations company based in Cambridge.1 It was founded in 2007.1

Last updated Oct 20, 2026.

Overview

2007Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCambridge1
  • Websitedicerna.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address75 Hayden Avenue, Lexington, Ma 024214
  • Filer categoryLarge accelerated filer4
  • LEI549300CTZMJMPH28WN393
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 42400863

See how the biggest companies compare on our leaderboards

Dicerna Pharmaceuticals (United States) image from its website
Image: dicerna.com5

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-68.9%Operating margin6
-68.6%Net margin6
587.4%Revenue growth, 20206
-81.8%Return on equity6
$163.4MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development100¢$205.4M
  • Interest0¢$20.0K

Out of $164.3M in revenue.6 The company lost money this year.

Where each dollar of operating cash went, fiscal 2020

  • Capital spending7¢$11.7M
  • Kept or used elsewhere93¢$163.4M

Out of $175.1M of cash from operations.6

Financial statements

Revenue789106$164.3M in 2020
0$50.0M$100.0M$150.0M$200.0M2014: $0$020142015: $184.0K$184.0K20152016: $0$020162017: $1.0M$1.0M20172018: $6.2M$6.2M2018+500%2019: $23.9M$23.9M2019+287%2020: $164.3M$164.3M2020+587%
Operating income1189106-$113.2M in 2020+151% since 2014
-$150.0M-$100.0M-$50.0M02014: -$45.1M-$45.1M20142015: -$63.0M-$63.0M2015+40%2016: -$59.7M-$59.7M2016−5%2017: -$60.7M-$60.7M2017+2%2018: -$90.4M-$90.4M2018+49%2019: -$128.2M-$128.2M2019+42%2020: -$113.2M-$113.2M2020−12%
Net income1189106-$112.7M in 2020+135% since 2014
-$150.0M-$100.0M-$50.0M02014: -$47.9M-$47.9M20142015: -$62.8M-$62.8M2015+31%2016: -$59.5M-$59.5M2016−5%2017: -$60.2M-$60.2M2017+1%2018: -$88.9M-$88.9M2018+48%2019: -$120.5M-$120.5M2019+36%2020: -$112.7M-$112.7M2020−6%
Fiscal year2014201520162017201820192020
Revenue$07$184.0K8$09$1.0M10$6.2M6$23.9M6$164.3M6
Research and development$29.5M11$44.0M8$41.4M9$35.9M10$45.7M6$109.3M6$205.4M6
Operating income-$45.1M11-$63.0M8-$59.7M9-$60.7M10-$90.4M6-$128.2M6-$113.2M6
Interest$199.0K11$09$010$603.0K6$3.0K6$20.0K6
Net income-$47.9M11-$62.8M8-$59.5M9-$60.2M10-$88.9M6-$120.5M6-$112.7M6

Compare Dicerna Pharmaceuticals (United States) with another company

Corporate structure

Dicerna Pharmaceuticals (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Dicerna Pharmaceuticals (United States)

  • BALYASNY ASSET MANAGEMENT L.P. Filed SC 13G/A on Dicerna Pharmaceuticals (United States), latest Feb 14, 2022 (2 filings since Dec 3, 2021)
  • Dicerna Pharmaceuticals (United States) Watertown, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Dicerna Pharmaceuticals (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$13.6M10 Dec 31, 2019$8.0M10 Dec 31, 2018+69.9%
Accumulated depreciation$6.6M10 Dec 31, 2019$5.3M10 Dec 31, 2018+23.6%
Property and equipment, net$7.1M10 Dec 31, 2019$2.7M10 Dec 31, 2018+160.3%
Finance-lease assets$187.0K6 Dec 31, 2020$186.0K10 Dec 31, 2019+0.5%
Operating-lease assets (leased space)$60.8M6 Dec 31, 2020$30.1M6 Dec 31, 2019+102.1%

Real estate and locations

ItemLatestA year beforeChange
Area of real estate91,728 sq ft6 Jul 1, 2020

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$126.0M6 Dec 31, 2020$152.8M6 Dec 31, 2019−17.5%

Leadership

Who has led Dicerna Pharmaceuticals (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Douglas Fambrough2014–2021

President

  1. Douglas Fambrough2020–2021

Chief financial officer

  1. James E. Dentzer2014–2015
  2. John B. Green2016–2020
  3. Douglas W. Pagan2020–2021

Chief operating officer

  1. James B. Weissman2019–2021
2010201520202025
Board members and other officers (25)

Timeline

  1. Dec 28, 20218-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights43
  2. Nov 18, 20218-K Entered a material agreement; Other events44
  3. Nov 9, 20218-K Results of operations45
  4. Jan 29, 2014New chief executive Douglas Fambrough becomes CEO13
  5. 2007Founded Founded1

Calendar

When it reported results

  1. Nov 9, 2021Reported quarterly or annual results45

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

54 filings to the SEC since October 2021: 1 quarterly reports, 3 major events, 25 insider forms, 2 large holders, 23 other. The latest 20:

  1. Feb 14, 2022SC 13G/A EDGAR
  2. Jan 10, 202215-12B EDGAR
  3. Dec 30, 2021EFFECT EDGAR
  4. Dec 30, 2021EFFECT EDGAR
  5. Dec 30, 2021EFFECT EDGAR
  6. Dec 30, 2021EFFECT EDGAR
  7. Dec 29, 20214 EDGAR
  8. Dec 29, 20214 EDGAR
  9. Dec 29, 20214 EDGAR
  10. Dec 29, 20214 EDGAR
  11. Dec 29, 20214 EDGAR
  12. Dec 29, 20214 EDGAR
  13. Dec 29, 20214 EDGAR
  14. Dec 29, 20214 EDGAR
  15. Dec 29, 20214 EDGAR
  16. Dec 29, 20214 EDGAR
  17. Dec 29, 20214 EDGAR
  18. Dec 29, 20214 EDGAR
  19. Dec 29, 20214 EDGAR
  20. Dec 29, 20214 EDGAR

The 54 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 18, 2021Brown Bob DChief Scientific Ofr., EVP R&DSale24,936$37.94$946.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Dicerna Pharmaceuticals (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDicerna Pharmaceuticals Inc2
  • CIK0001399529
  • Employer ID (EIN)20-59936092
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address75 Hayden Avenue, Lexington, MA 024212
  • Phone617 621 80972
  • Shares outstanding77,888,932 as of Nov 4, 202147
  • Public float$1.8B as of Jun 30, 20206
  • On EDGAR sinceMay 1, 20072
  • Filings657 in all: 4 (295), 8-K (101), 3 (39), SC 13G/A (30), 10-Q (24), SC 13D/A (17), SC 13G (12), 4/A (9)2
    All 50 form types

    EFFECT (9), 10-K (8), DEF 14A (8), DEFA14A (8), 424B5 (7), CORRESP (7), S-8 (6), S-8 POS (6), SC 13D (6), UPLOAD (6), CT ORDER (5), S-1/A (5), POS AM (4), S-3 (4), SC 14D9/A (4), 8-K/A (3), D (3), SC TO-T/A (3), 424B3 (2), 5 (2), S-3/A (2), SC14D9C (2), 10-K/A (1), 10-Q/A (1), 15-12B (1), 25-NSE (1), 3/A (1), 424B4 (1), 424B7 (1), 8-A12B (1), CERTNAS (1), D/A (1), DEFR14A (1), DRS (1), FWP (1), POSASR (1), REGDEX (1), S-1 (1), S-3ASR (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2021
    Quarterly report (10-Q) Nov 9, 2021
    Proxy statement (DEF 14A) Apr 20, 2021
    Latest 8-K (8-K) Dec 28, 2021

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47